Advertisement

Archives of Virology

, Volume 153, Issue 3, pp 507–515 | Cite as

T-even-related bacteriophages as candidates for treatment of Escherichia coli urinary tract infections

  • H. Nishikawa
  • M. Yasuda
  • J. Uchiyama
  • M. Rashel
  • Y. Maeda
  • I. Takemura
  • S. Sugihara
  • T. Ujihara
  • Y. Shimizu
  • T. Shuin
  • S. Matsuzaki
Original Article

Abstract

Multidrug-resistant uropathogenic Escherichia coli (UPEC) is increasing gradually on a worldwide scale. We therefore examined the possibility of bacteriophage (phage) therapy for urinary tract infections (UTIs) caused by the UPEC strains as an alternative to chemotherapy. In addition to the well-known T4 phage, KEP10, which was newly isolated, was used as a therapeutic phage candidate. KEP10 showed a broader bacteriolytic spectrum (67%) for UPEC strains than T4 (14%). Morphological and genetic analyses showed that KEP10 resembles phage T4. Phages T4 and KEP10 injected into the peritoneal cavity of mice were distributed immediately to all organs examined and maintained a high titer for at least 24 h. They were stable in the urine of both mice and humans for 24 h at 37°C. Administration of these phages into the peritoneal cavity caused a marked decrease in the mortality of mice inoculated transurethrally with a UPEC strain, whereas most of the control mice died within a few days of bacterial infection. Inoculation with phage alone produced no adverse effects attributable to the phage per se. The present study experimentally demonstrated the therapeutic potential of phage for E. coli-induced UTIs, and T-even-related phages may be suitable candidates with which to treat them.

Keywords

Major Capsid Protein Phage Therapy Mouse Urine UPEC Strain Bacterial Infectious Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This work was partly supported by grants from the Ministry of Education, Science, Sports, and Culture, Japan [16659265].

References

  1. 1.
    Ackermann HW (2007) 5500 bacteriophages examined in the electron microscope. Arch Virol 152:227–243PubMedCrossRefGoogle Scholar
  2. 2.
    Alisky J, Iczkowski K, Rapoport A, Troitsky N (1998) Bacteriophages show promise as antimicrobial agents. J Infect 36:5–15PubMedCrossRefGoogle Scholar
  3. 3.
    Barrow P, Lovell M, Berchieri A Jr (1998) Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin Diagn Lab Immunol 5:294–298PubMedGoogle Scholar
  4. 4.
    Carlton RM (1999) Phage therapy: past history and future prospects. Arch Immunol Ther Exp 47:267–274Google Scholar
  5. 5.
    Chibani-Chennoufi S, Sidoti J, Bruttin A, Dillmann M-L, Kutter E, Qadri F, Sarker SA, Brüssow H (2004) Isolation of Escherichia coli bacteriophages from the stool of pediatric diarrhea patients in Bangladesh. J Bacteriol 186:8287–8294PubMedCrossRefGoogle Scholar
  6. 6.
    Filée J, Tétart F, Suttle CA, Krisch HM (2005) Marine T4-type bacteriophages, a ubiquitous component of the dark matter of the biosphere. Proc Natl Acad Sci 102:12471–12476PubMedCrossRefGoogle Scholar
  7. 7.
    Geier MR, Trigg ME, Merril CR (1973) Fate of bacteriophage lambda in non-immune germ-free mice. Nature 246:221–223PubMedCrossRefGoogle Scholar
  8. 8.
    Glantz SA (2002) Primer of biostatistics, 5th edn. McGrau Hill Medical Publishing Division. New YorkGoogle Scholar
  9. 9.
    Ho K (2001) Bacteriophage therapy for bacterial infections. Rekindling a memory from the pre-antibiotics era. Perspect Biol Med 44:1–16PubMedCrossRefGoogle Scholar
  10. 10.
    Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM (2003) Evaluation of aerosol spray and intramuscular injection of bacteriophage to treat an Escherichia coli respiratory infection. Poult Sci 82:1108–1112PubMedGoogle Scholar
  11. 11.
    Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM (2003) Bacteriophage treatment of a severe Escherichia coli respiratory infection in broiler chickens. Avian Dis 47:1399–1405PubMedCrossRefGoogle Scholar
  12. 12.
    Huff WE, Huff GR, Rath NC, Donoghue AM (2006) Evaluation of the influence of bacteriophage titer on the treatment of colibacillosis in broiler chickens. Poult Sci 85:1373–1377PubMedGoogle Scholar
  13. 13.
    Matsuzaki S, Inoue T, Tanaka S (1998) A vibriophage, KVP40, with major capsid protein homologous to gp23* of coliphage T4. Virology 242:314–318PubMedCrossRefGoogle Scholar
  14. 14.
    Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, Shen Y, Jin Z, Fujimoto S, Nasimuzzaman MD, Wakiguchi H, Sugihara S, Sugiura T, Koda S, Muraoka A, Imai S (2003) Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage ϕMR11. J Infect Dis 187:613–624PubMedCrossRefGoogle Scholar
  15. 15.
    Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S (1996) Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci USA 93:3188–3192PubMedCrossRefGoogle Scholar
  16. 16.
    Merril CR, Scholl D, Adhya L (2003) The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2:489–497PubMedCrossRefGoogle Scholar
  17. 17.
    Muratani T, Matsumoto T (2004) Bacterial resistance to antimicrobials in urinary isolates. Int J Antimicrob Agents 24S:S28–S31CrossRefGoogle Scholar
  18. 18.
    Pena C, Gudiol C, Tubau F, Saballs M, Pujol M, Dominguez MA, Calatayud L, Ariza J, Gudiol F (2006) Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect 12:279–284PubMedCrossRefGoogle Scholar
  19. 19.
    Sahm DF, Thornsberry C, Mayfield DC, Jones ME (2001) Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographics in the United States in 2000. Antimicrob Agents Chemother 45:1402–1406PubMedCrossRefGoogle Scholar
  20. 20.
    Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring HarborGoogle Scholar
  21. 21.
    Smith HW, Huggins MB (1982) Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 128:307–318PubMedGoogle Scholar
  22. 22.
    Smith HW, Huggins MB (1983) Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets, and lambs. J Gen Microbiol 129:2659–2675PubMedGoogle Scholar
  23. 23.
    Smith HW, Huggins MB, Shaw KM (1987) The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol 133:1111–1126PubMedGoogle Scholar
  24. 24.
    Smith HW, Huggins MB, Shaw KM (1987) Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. J Gen Microbiol 133:1127–1135PubMedGoogle Scholar
  25. 25.
    Sulakvelidze A, Alavidze Z, Morris JG Jr (2001) Bacteriophage therapy. Antimicrob Agents Chemother 45:649–659PubMedCrossRefGoogle Scholar
  26. 26.
    Summers WC (1999) Félix d’Herelle and the origins of molecular biology. Yale University Press, New HavenGoogle Scholar
  27. 27.
    Tétart F, Desplats C, Krisch HM (1998) Genome plasticity in the distal tail fiber locus of the T-even bacteriophage: recombination between conserved motifs swaps adhesin specificity. J Mol Biol 282:543–556PubMedCrossRefGoogle Scholar
  28. 28.
    Tétart F, Desplats C, Kutateladze M, Monod C, Ackermann HW, Krisch M (2001) Phylogeny of the major head and tail genes of the wide-ranging T4-type bacteriophages. J Bacteriol 183:358–366PubMedCrossRefGoogle Scholar
  29. 29.
    Thacker PD (2003) Set a microbe to kill a microbe: drug resistance renews interest in phage therapy. JAMA 290:3183–3185PubMedCrossRefGoogle Scholar
  30. 30.
    Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, Sumiyama Y, Uchiyama J, Sakurai S, Matsuzaki S, Imai S, Yamaguchi K (2007) Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 51:446–452PubMedCrossRefGoogle Scholar
  31. 31.
    Weber-Dabrowska B, Mulczyk M, Górski A (2000) Bacteriophage therapy of bacterial infections: an update of our institute’s experience. Arch Immunol Ther Exp 48:547–551Google Scholar
  32. 32.
    Zuber S, Ngom-Bru C, Barretto C, Bruttin A, Brüssow H, Denou H (2007) Genome analysis of phage JS98 defines a fourth major subgroup of T4-like phages in Escherichia coli. J Bacteriol 189:8206–8214PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • H. Nishikawa
    • 1
  • M. Yasuda
    • 1
  • J. Uchiyama
    • 2
    • 3
  • M. Rashel
    • 3
  • Y. Maeda
    • 2
    • 3
  • I. Takemura
    • 3
    • 4
  • S. Sugihara
    • 5
  • T. Ujihara
    • 6
  • Y. Shimizu
    • 3
  • T. Shuin
    • 1
  • S. Matsuzaki
    • 3
  1. 1.Department of UrologyKochi Medical SchoolNankoku, KochiJapan
  2. 2.Department of PediatricsKochi Medical SchoolNankoku, KochiJapan
  3. 3.Department of Microbiology and InfectionKochi Medical SchoolNankoku, KochiJapan
  4. 4.Department of BiochemistryKochi Medical SchoolNankoku, KochiJapan
  5. 5.Clinical Laboratory Center of Kochi Medical School HospitalKochi Medical SchoolNankoku, KochiJapan
  6. 6.Section of Life Science and Biofunctional MaterialsScience Research Center of Kochi UniversityNankoku, KochiJapan

Personalised recommendations